Exsilio
PrivateLast Round
Series A
Jun 25, 2024
Total Funding Raised
$82M
Company Overview
Exsilio is a biotechnology company that develops genomic medicines delivered in lipid nanoparticles to safely and effectively treat a wide array of diseases, including genetic disorders, cancer, and autoimmune conditions, by utilizing technology that precisely inserts new genes into cells via RNA intermediate templates.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Exsilio Comps
Public and private peers based on sector, stage, and business model.
Exsilio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jun 25, 2024 |
Exsilio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Deep Insight | Series A |
| Innovation Endeavors | Series A |
| OrbiMed | Series A, Seed |
| Novartis Venture Fund | Series A |
| Arc Ventures | Series A |
| Delos Capital Partners | Series A |
| Invus | Series A |
Exsilio Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Exsilio's valuation, stock price, and market status.
